The year 2023 has seen the first CRISPR therapy indicate it could be a one-time success for patients with sickle cell disease as well as more movement in the field of Alzheimer’s disease. In this video, the Clinical Trials Arena evaluates some significant trials of the year as well as some important regulatory changes in both Europe and the US.
Go deeper with GlobalData
